Current Status and Future Prospects of Stem Cell Therapy for Infertile Patients with Premature Ovarian Insufficiency

Hye Kyeong Kim,Tae Jin Kim

DOI: https://doi.org/10.3390/biom14020242

IF: 6.064

2024-02-20

Biomolecules

Abstract:Premature ovarian insufficiency (POI), also known as premature menopause or premature ovarian failure, signifies the partial or complete loss of ovarian endocrine function and fertility before 40 years of age. This condition affects approximately 1% of women of childbearing age. Although 5–10% of patients may conceive naturally, conventional infertility treatments, including assisted reproductive technology, often prove ineffective for the majority. For infertile patients with POI, oocyte donation or adoption exist, although a prevalent desire persists among them to have biological children. Stem cells, which are characterized by their undifferentiated nature, self-renewal capability, and potential to differentiate into various cell types, have emerged as promising avenues for treating POI. Stem cell therapy can potentially reverse the diminished ovarian endocrine function and restore fertility. Beyond direct POI therapy, stem cells show promise in supplementary applications such as ovarian tissue cryopreservation and tissue engineering. However, technological and ethical challenges hinder the widespread clinical application of stem cells. This review examines the current landscape of stem cell therapy for POI, underscoring the importance of comprehensive assessments that acknowledge the diversity of cell types and functions. Additionally, this review scrutinizes the limitations and prospects associated with the clinical implementation of stem cell treatments for POI.

biochemistry & molecular biology

What problem does this paper attempt to address?

This paper aims to explore the current status of Premature Ovarian Insufficiency (POI) and the future prospects of stem cell therapy in treating POI. Specifically:

1. **Background**: POI is a condition characterized by partial or complete loss of ovarian function before the age of 40, affecting approximately 1% of women of reproductive age. Although 5-10% of patients may conceive naturally, most traditional assisted reproductive technologies have limited effectiveness for POI patients.

2. **Research Objectives**: Due to their undifferentiated nature, self-renewal capability, and ability to differentiate into various cell types, stem cells show great potential in restoring ovarian endocrine function and fertility in POI patients. This paper reviews the current progress of stem cell therapy in the treatment of POI and discusses the related technical and ethical challenges.

Through this review, the authors hope to provide a new treatment avenue for POI patients and explore the potential and limitations of stem cell therapy in future clinical applications.